{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"14"}],"units":"Participants"}],"groups":[{"description":"INCB053914 will be self-administered orally once a day as a 100mg immediate release monotherapy dose.","id":"OG000","title":"Parts 1 and 2: INCB053914 100 mg QD"},{"description":"INCB053914 will be self-administered orally twice day as a 50mg immediate release monotherapy dose.","id":"OG001","title":"Parts 1 and 2: INCB053914 50 mg BID"},{"description":"INCB053914 will be self-administered orally twice day in as a 65mg immediate release monotherapy dose","id":"OG002","title":"Parts 1 and 2: INB053914 65 mg BID"},{"description":"INCB053914 will be self-administered orally twice day in as a 80mg immediate release monotherapy dose.","id":"OG003","title":"Parts 1 and 2: INB053914 80 mg BID"},{"description":"INCB053914 will be self-administered orally twice day as a 100mg immediate release monotherapy dose.","id":"OG004","title":"Parts 1 and 2: INB053914 100 mg BID"},{"description":"INCB053914 will be self-administered orally twice day as a 115mg immediate release monotherapy dose.","id":"OG005","title":"Parts 1 and 2: INB053914 115 mg BID"},{"description":"Combination Treatment Group A: INCB053914 50 mg BID + Cytarabine","id":"OG006","title":"Parts 3 and 4: INCB053914 50 mg BID + Cytarabine"},{"description":"Combination Treatment Group B: INCB053914 50 mg BID + Azacitidine","id":"OG007","title":"Parts 3 and 4: INCB053914 50 mg BID + Azacitidine"},{"description":"Combination Treatment Group B: INCB053914 80 mg BID + Azacitine","id":"OG008","title":"Parts 3 and 4: INCB053914 80 mg BID + Azacitine"},{"description":"Combination Treatment Group C: INCB053914 50 mg BID + Ruxolitinib","id":"OG009","title":"Parts 3 & 4: INCB 053914 50 mg BID + Ruxolitinib"},{"description":"Combination Treatment Group C: INCB 053914 80 mg BID + Ruxolitinib","id":"OG010","title":"Parts 3 & 4: INCB 053914 80 mg + Ruxolitinib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Approximately 7 months","title":"Determination of the Safety and Tolerability of INCB053914 as Measured by the Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}